ProQR Therapeutics (NASDAQ:PRQR) Given New $10.00 Price Target at HC Wainwright

ProQR Therapeutics (NASDAQ:PRQR) had its price target boosted by HC Wainwright from $5.00 to $10.00 in a research report sent to investors on Friday,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock.

Separately, Raymond James raised ProQR Therapeutics from an “outperform” rating to a “strong-buy” rating and increased their price objective for the company from $6.00 to $14.00 in a report on Tuesday, October 29th. One analyst has rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $7.13.

ProQR Therapeutics Trading Up 5.0 %

NASDAQ:PRQR opened at $3.96 on Friday. The company has a market capitalization of $323.45 million, a P/E ratio of -12.50 and a beta of 0.26. ProQR Therapeutics has a 12 month low of $1.18 and a 12 month high of $4.62. The firm has a fifty day simple moving average of $2.51 and a 200-day simple moving average of $2.11.

Institutional Investors Weigh In On ProQR Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. EP Wealth Advisors LLC purchased a new stake in shares of ProQR Therapeutics in the first quarter worth about $26,000. Acadian Asset Management LLC acquired a new position in ProQR Therapeutics in the first quarter valued at approximately $56,000. BNP Paribas Financial Markets grew its stake in shares of ProQR Therapeutics by 120.1% during the 1st quarter. BNP Paribas Financial Markets now owns 35,001 shares of the biopharmaceutical company’s stock worth $80,000 after purchasing an additional 19,100 shares during the period. OneDigital Investment Advisors LLC grew its stake in shares of ProQR Therapeutics by 37.0% during the 3rd quarter. OneDigital Investment Advisors LLC now owns 57,550 shares of the biopharmaceutical company’s stock worth $105,000 after purchasing an additional 15,550 shares during the period. Finally, Ikarian Capital LLC increased its holdings in shares of ProQR Therapeutics by 2.3% during the 1st quarter. Ikarian Capital LLC now owns 483,583 shares of the biopharmaceutical company’s stock valued at $1,098,000 after purchasing an additional 10,958 shares in the last quarter. 32.65% of the stock is owned by institutional investors and hedge funds.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).